share_log

Maxim Group Initiates Coverage On Virpax Pharmaceuticals with Buy Rating, Announces Price Target of $4

Benzinga Real-time News ·  Jun 9, 2022 09:22

Maxim Group analyst Naz Rahman initiates coverage on Virpax Pharmaceuticals (NASDAQ:VRPX) with a Buy rating and announces Price Target of $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment